Access to well-characterized specimens and laboratory expertise is crucial to the success of each research study proposed within this SPORE program, and to the long-term success of translational research in ovarian cancer. This core will work in concert with all SPORE Cores, Projects and Developmental Research Studies to achieve program goals. The Specimen Core will continue to collect, process, characterize, store, and track tissue, blood samples and other unique specimens, expanding current repository contents for use in SPORE projects and developmental research studies. Our organized and comprehensive approach to specimen accrual and characterization includes (a) a systematic process for specimen collection (b) review to assure quality and consistency in pathologic analyses and (c) centralized management of specimens to facilitate distribution based on priorities defined by a Specimen Review Committee familiar with all POCRC research endeavors. Research laboratories associated with this Core provide critical services to SPORE research projects, including pathology review, antibody development, establishment and characterization of primary ovarian cancer cell cultures and cell lines, and conduct of timely assays for biomarker panel validation. It is essential that the Specimen Core continue to evolve to meet the changing needs of our SPORE program. Towards that end, this Core will emphasize protocols that maximize efficiency and fulfill project needs. For example, processing blood products into 0.3 ml serum and plasma aliquots eliminates harmful freeze-thaw cycles and ensures that the Early Detection Project receives high quality specimens for biomarker evaluation. Furthermore, addition of primary cell cultures to specimen processing protocols facilitates the work of the Immunotherapy and Molecular Targets Projects. Working in conjunction with the other three Cores, the Specimen Core will ensure that all projects, including developmental research studies, have access to a broad spectrum of specimens and data. Lastly, while established to primarily serve the needs of the SPORE projects, the resources of the Specimen Core have been created with sufficient flexibility such that SPORE collaborators may also utilize this very important scientific Core shared resource. Accordingly, specimen inventories will also be available to outside researchers and to other SPOREs through the new Virtual Shared Specimen Repository (VSSR).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083636-08
Application #
7246511
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2006-07-01
Budget End
2007-06-30
Support Year
8
Fiscal Year
2006
Total Cost
$263,891
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Kondrashova, Olga; Topp, Monique; Nesic, Ksenija et al. (2018) Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 9:3970
Hooda, Jagmohan; Novak, Marian; Salomon, Matthew P et al. (2018) Early loss of Histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res :
Au-Yeung, George; Lang, Franziska; Azar, Walid J et al. (2017) Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 23:1862-1874
Liu, Joyce F; Palakurthi, Sangeetha; Zeng, Qing et al. (2017) Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res 23:1263-1273
Zheng, Grace X Y; Terry, Jessica M; Belgrader, Phillip et al. (2017) Massively parallel digital transcriptional profiling of single cells. Nat Commun 8:14049
Kroeger Jr, Paul T; Drapkin, Ronny (2017) Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29:26-34
Yu-Rice, Yi; Edassery, Seby L; Urban, Nicole et al. (2017) Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer. Reproduction 153:277-284
Liao, John B; Swensen, Ron E; Ovenell, Kelsie J et al. (2017) Phase II trial of albumin-bound paclitaxel and granulocyte macrophage colony-stimulating factor as an immune modulator in recurrent platinum resistant ovarian cancer. Gynecol Oncol 144:480-485
Vragniau, Charles; Hübner, Jens-Martin; Beidler, Peter et al. (2017) Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy. J Virol 91:
Kondrashova, Olga; Nguyen, Minh; Shield-Artin, Kristy et al. (2017) Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. Cancer Discov 7:984-998

Showing the most recent 10 out of 187 publications